Capital International Inc. CA Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Inc. CA purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,375 shares of the biotechnology company's stock, valued at approximately $1,153,000.

A number of other hedge funds also recently bought and sold shares of the stock. Capital International Investors increased its stake in shares of Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after buying an additional 753,859 shares during the period. FIL Ltd grew its holdings in Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after acquiring an additional 89,016 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Ascendis Pharma A/S by 17.5% in the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock valued at $56,072,000 after purchasing an additional 60,548 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after purchasing an additional 39,309 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Ascendis Pharma A/S by 94.4% during the 4th quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after purchasing an additional 37,593 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have issued reports on ASND. UBS Group began coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald boosted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 25th. Royal Bank of Canada assumed coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 target price for the company. Finally, Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $204.67.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded up $3.70 during trading hours on Friday, reaching $164.15. 560,140 shares of the company's stock were exchanged, compared to its average volume of 488,000. The company's 50 day moving average is $153.64 and its two-hundred day moving average is $138.68. The company has a market cap of $10.01 billion, a P/E ratio of -23.12 and a beta of 0.54. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.